Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Nicolas Pauillac
KEPL
Nicolas Pauillac
Kepler Capital
Wall Street Analyst
Not yet ranked — too few measurable calls.
100%
Success Rate
+82.0%
Average Return
2 of 2 calls profitable · +58.1% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 100% of Nicolas Pauillac's ratings turned a profit when each position was held for 1 year — averaging +82.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

76 Buy 17 Hold 0 Sell
Nicolas's Stock Coverage 27 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GB:GSK
GlaxoSmithKline
 May 26, 2026 BUY Hold
-2.9% avg upside
25 analysts
$2516.00
30.73% Upside
 ·
CH:SDZ
Sandoz Group Ltd
 May 11, 2026 BUY Buy
-7.8% avg upside
10 analysts
$80.00
17.70% Upside
 ·
CH:COPN
COSMO Pharmaceuticals N.V.
 May 11, 2026 BUY Strong Buy
+109.2% avg upside
3 analysts
$130.00
89.75% Upside
 ·
FR:CVX
Affluent Medical SA
 May 04, 2026 BUY Strong Buy
+41.1% avg upside
1 analyst
$5.00
41.15% Upside
 ·
FR:OSE
OSE Immunotherapeutics SA
 Apr 30, 2026 BUY Strong Buy
+229.3% avg upside
4 analysts
$8.20
134.80% Upside
 ·
CH:IDIA
Idorsia Ltd
 Apr 28, 2026 BUY Hold
-26.7% avg upside
8 analysts
$4.50
20.73% Downside
 ·
CH:BION
BB Biotech
 Apr 24, 2026 BUY Strong Buy
+60.4% avg upside
1 analyst
$73.00
60.35% Upside
 ·
FR:SAN
Sanofi
 Apr 23, 2026 HOLD Strong Buy
+32.9% avg upside
30 analysts
$85.00
14.64% Upside
 ·
DE:FYB
Formycon AG
 Apr 22, 2026 BUY Strong Buy
+153.3% avg upside
5 analysts
$33.00
67.19% Upside
 ·
GB:0QIU
Novo Nordisk
 Apr 20, 2026 HOLD Hold
+43.2% avg upside
28 analysts
$280.00
0.07% Upside
 ·
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
 Apr 01, 2026 BUY Strong Buy
+30.4% avg upside
1 analyst
$20.30
30.40% Upside
 ·
FR:MEDCL
MedinCell SA
 Mar 06, 2026 BUY Strong Buy
+24.9% avg upside
3 analysts
$36.60
52.01% Upside
 ·
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
 Feb 25, 2026 BUY Strong Buy
+194.9% avg upside
3 analysts
$5.00
72.37% Upside
 ·
FR:VIRP
Virbac SA
 Jul 17, 2025 HOLD Buy
+5.2% avg upside
3 analysts
$390.00
14.56% Upside
 ·
FR:ALBPS
Biophytis SA
 May 06, 2024 SELL Strong Sell
+4083.0% avg upside
1 analyst
$0.64
4082.97% Upside
 ·
NL:LKFT
Galapagos
 May 03, 2024 HOLD Sell
+112.9% avg upside
16 analysts
$41.00
66.81% Upside
 ·
LKFT
Lakefront Biotherapeutics
 May 03, 2024 HOLD Hold
+272.6% avg upside
24 analysts
$47.06
66.31% Upside
 ·
GB:0QW0
arGEN X
 Feb 20, 2024 HOLD Strong Buy
-24.9% avg upside
24 analysts
$375.00
51.55% Downside
 ·
ARGX
Argenx Se
 Feb 20, 2024 HOLD Strong Buy
-15.9% avg upside
46 analysts
$430.44
50.98% Downside
 +63.8%
NYXH
Nyxoah
 Jan 10, 2024 BUY Strong Buy
+851.6% avg upside
12 analysts
$13.77
760.96% Upside
 +100.2%
CH:BSLN
Basilea Pharmaceutica
 Nov 20, 2023 BUY Strong Buy
+42.6% avg upside
6 analysts
$57.00
11.07% Upside
 ·
FR:MAAT
MaaT Pharma
 Sep 07, 2023 BUY Strong Buy
+477.9% avg upside
2 analysts
$16.00
460.40% Upside
 ·
FR:VLA
Valneva
 Aug 28, 2023 BUY Strong Buy
+289.1% avg upside
3 analysts
$9.00
290.54% Upside
 ·
DE:52U
Hyloris Pharmaceuticals SA
 Jun 22, 2023 BUY Strong Buy
+250.0% avg upside
2 analysts
$17.00
280.24% Upside
 ·
FR:ALVIO
Valerio Therapeutics
 May 03, 2023 BUY Buy
+127.0% avg upside
3 analysts
$0.40
93.29% Upside
 ·
FR:ALCOX
Nicox SA
 Apr 28, 2023 BUY Strong Buy
+1564.5% avg upside
5 analysts
$2.70
599.54% Upside
 ·
FR:ABVX
Abivax SA
 Dec 21, 2022 BUY Strong Buy
-63.4% avg upside
3 analysts
$16.00
81.22% Downside
 ·
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Nicolas Pauillac — Frequently Asked Questions
How accurate are Nicolas Pauillac's stock ratings?
Based on the calls 13Foresight could measure, about 100% of Nicolas's ratings were profitable over a one-year hold, with an average return of +82.0% per rating, or +58.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Nicolas ranked on 13Foresight?
Nicolas Pauillac is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Nicolas cover?
Nicolas most recently has ratings on GB:GSK, CH:SDZ, CH:COPN, FR:CVX, FR:OSE, CH:IDIA, CH:BION, FR:SAN, DE:FYB, GB:0QIU, DE:EUZ, FR:MEDCL and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.